Similarly, Fang et al. identified C12orf5, encoding TP53 induced glycolysis and apoptosis regulator (TIGAR), as a novel therapeutic target able to modulate ovarian cancer sensitivity to the PARP inhibitor olaparib [87]. The gene discussed is TP53; the disease is ovarian carcinoma.